Abbott Laboratories Balance Sheet
NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:02 PM ET · Delayed 15 min
Abbott Laboratories financial position
At the end of fiscal 2025, Abbott Laboratories reported total assets of $86.71 billion, up 6.5% from a year earlier against total liabilities of $33.94 billion. Shareholders' equity stood at $52.13 billion, or 60.1% of assets. The company held $8.52 billion in cash and equivalents against $12.93 billion of debt, a net debt position of $4.41 billion.
The current ratio (current assets divided by current liabilities) was 1.58, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.25.
Summary generated from market data by MetaCap's automated system. Methodology
Abbott Laboratories balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.52B | 7.62B | 6.90B | 9.88B | 9.80B | 6.84B | 3.86B | 3.84B | 9.41B | 18.62B |
| Short-Term Investments | 417.00M | 351.00M | 383.00M | 288.00M | 450.00M | 310.00M | 280.00M | 242.00M | 203.00M | 155.00M |
| Receivables | 7.93B | 6.92B | 6.57B | 6.22B | 6.49B | 6.41B | 5.42B | 5.18B | 5.25B | 3.25B |
| Inventory | 6.49B | 6.19B | 6.57B | 6.17B | 5.16B | 5.01B | 4.32B | 3.80B | 3.60B | 2.43B |
| Total Current Assets | 26.00B | 23.66B | 22.67B | 25.22B | 24.24B | 20.44B | 15.67B | 14.63B | 20.15B | 26.78B |
| Property, Plant & Equipment | 11.82B | 10.66B | 10.15B | 9.16B | 8.96B | 9.03B | 8.04B | 7.56B | 7.61B | 5.71B |
| Goodwill | 24.04B | 23.11B | 23.68B | 22.80B | 23.23B | 23.74B | 23.20B | 23.25B | 24.02B | 7.68B |
| Intangible Assets | 5.53B | 6.65B | 8.81B | 10.45B | 12.74B | 14.78B | 17.02B | 18.94B | 21.47B | 4.54B |
| Long-Term Investments | 918.00M | 886.00M | 799.00M | 766.00M | 816.00M | 821.00M | 883.00M | 897.00M | 883.00M | 2.95B |
| Total Assets | 86.71B | 81.41B | 73.21B | 74.44B | 75.20B | 72.55B | 67.89B | 67.17B | 76.25B | 52.67B |
| Accounts Payable | 4.24B | 4.20B | 4.29B | 4.61B | 4.41B | 3.95B | 3.25B | 2.98B | 2.40B | 1.18B |
| Short-Term Debt | 3.03B | 1.50B | 1.08B | 2.25B | 754.00M | 220.00M | 1.48B | 207.00M | 714.00M | 1.32B |
| Total Current Liabilities | 16.50B | 14.16B | 13.84B | 15.49B | 13.11B | 11.91B | 10.86B | 9.01B | 8.91B | 6.66B |
| Long-Term Debt | 9.90B | 12.63B | 13.60B | 14.52B | 17.30B | 18.53B | 16.66B | 19.36B | 27.21B | 20.68B |
| Total Liabilities | 33.94B | 33.51B | 34.39B | 37.53B | 39.17B | 39.55B | 36.59B | 36.45B | 45.15B | 31.95B |
| Shareholders' Equity | 52.13B | 47.66B | 38.60B | 36.69B | 35.80B | 32.78B | 31.09B | 30.52B | 30.90B | 20.54B |
| Retained Earnings | 49.78B | 47.26B | 37.55B | 35.26B | 31.53B | 27.63B | 25.85B | 24.56B | 23.98B | 25.57B |
| Total Debt | 12.93B | 14.13B | 14.68B | 16.77B | 18.05B | 18.75B | 18.14B | 19.57B | 27.92B | 22.01B |
| Net Cash (Debt) | -3.99B | -6.16B | -7.40B | -6.60B | -7.80B | -11.60B | -14.00B | -15.48B | -18.31B | -3.23B |
This table shows 10 annual periods of Abbott Laboratories's balance sheet, from FY 2025 back to FY 2016, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ABT's reporting calendar. What is a balance sheet?